Permanent inhibition of viral entry by covalent entrapment of HIV gp41 on the virus surface

Biochemistry

Volumn 50, Issue 32, 2011, Pages 6966-6972

  Yi, Hyun Ah ^a   Diaz Aguilar, Barbara ^a   Bridon, Dominique ^b   Quraishi, Omar ^c   Jacobs, Amy ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Optivia Biotechnology Inc   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOPREVENTIVE AGENTS; CONFORMATIONAL CHANGE; CONFORMATIONAL INTERMEDIATES; COVALENT ENTRAPMENT; ENVELOPE PROTEINS; HETERODIMERS; HOST CELLS; INHIBITORY PEPTIDES; MEMBRANE FUSION; REACTIVE GROUP; TRANSMEMBRANES;

CELL MEMBRANES; OLIGOMERS; PEPTIDES; VIRUSES;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PEPTIDE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CHEMOPROPHYLAXIS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COVALENT BOND; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRUS ENTRY; VIRUS INHIBITION;

AMINO ACID SEQUENCE; CELL LINE; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE FUSION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 80051505242     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi201014b     Document Type: Article

References (46)

1. Cai, L. and Jiang, S. (2010) Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41 ChemMedChem 5, 1813-1824
2. Chan, D. C. and Kim, P. S. (1998) HIV Entry and Its Inhibition Cell 93, 681-684 (Pubitemid 28257575)
3. Furuta, R. A., Wild, C. T., Weng, Y., and Weiss, C. D. (1998) Capture of an early fusion-active conformation of HIV-1 gp41 Nat. Struct. Biol. 5, 276-279 (Pubitemid 28164878)
4. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl. Acad. Sci. U. S. A. 91, 9770-9774 (Pubitemid 24311889)
5. Shai, Y. (2000) Functional domains within fusion proteins: prospectives for development of peptide inhibitors of viral cell fusion Biosci. Rep. 20, 535-555 (Pubitemid 32523210)
6. Kliger, Y. and Shai, Y. (2000) Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation J. Mol. Biol. 295, 163-168 (Pubitemid 30045350)
7. Kliger, Y., Gallo, S. A., Peisajovich, S. G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., and Shai, Y. (2001) Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage J. Biol. Chem. 276, 1391-1397 (Pubitemid 32096570)
8. Eckert, D. M. and Kim, P. S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region Proc. Natl. Acad. Sci. U. S. A. 98, 11187-11192 (Pubitemid 32928704)
9. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., and Hunter, E. (2001) Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor J. Virol. 75, 8605-8614 (Pubitemid 32768965)
10. Bewley, C. A., Louis, J. M., Ghirlando, R., and Clore, G. M. (2002) Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41 J. Biol. Chem. 277, 14238-14245 (Pubitemid 34968038)
11. Gallo, S. A., Sackett, K., Rawat, S. S., Shai, Y., and Blumenthal, R. (2004) The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors J. Mol. Biol. 340, 9-14 (Pubitemid 38739433)
12. Jacobs, A., Quraishi, O., Huang, X., Bousquet-Gagnon, N., Nault, G., Francella, N., Alvord, W. G., Pham, N., Soucy, C., Robitaille, M., Bridon, D., and Blumenthal, R. (2007) A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex J. Biol. Chem. 282, 32406-32413 (Pubitemid 350106447)
13. Lu, M., Blacklow, S. C., and Kim, P. S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein Nat. Struct. Biol. 2, 1075-1082
14. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl. Acad. Sci. U. S. A. 94, 12303-12308 (Pubitemid 27492523)
15. Caffrey, M., Cai, M., Kaufman, J., Stahl, S. J., Wingfield, P. T., Covell, D. G., Gronenborn, A. M., and Clore, G. M. (1998) Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41 EMBO J. 17, 4572-4584 (Pubitemid 28377158)
16. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein Cell 89, 263-273 (Pubitemid 27199898)
17. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41 Nature 387, 426-430 (Pubitemid 27227210)
18. Jacobs, A., Simon, C., and Caffrey, M. (2006) Thermostability of the HIV gp41 wild-type and loop mutations Protein Pept. Lett. 13, 477-480
19. Caffrey, M. (2001) Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop Biochim. Biophys. Acta 1536, 116-122 (Pubitemid 32530810)
20. Krell, T., Greco, F., Engel, O., Dubayle, J., Kennel, A., Charloteaux, B., Brasseur, R., Chevalier, M., Sodoyer, R., and El Habib, R. (2004) HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants Eur. J. Biochem. 271, 1566-1579 (Pubitemid 38553562)
21. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide Nature 365, 113
22. Wild, C., Greenwell, T., Shugars, D., Rimsky-Clarke, L., and Matthews, T. (1995) The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure AIDS Res. Hum. Retroviruses 11, 323-325
23. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition Proc. Natl. Acad. Sci. U. S. A. 89, 10537-10541
24. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41 Biochem. Biophys. Res. Commun. 195, 533-538 (Pubitemid 23280449)
25. Neurath, A. R., Strick, N., and Jiang, S. (1992) Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1) Virology 188, 1-13
26. Lu, M. and Kim, P. S. (1997) A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein J. Biomol. Struct. Dyn. 15, 465-471 (Pubitemid 28035859)
27. Noah, E., Biron, Z., Naider, F., Arshava, B., and Anglister, J. (2008) The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide Biochemistry 47, 6782-6792 (Pubitemid 351898933)
28. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., and Jiang, S. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J. Biol. Chem. 280, 11259-11273 (Pubitemid 40418432)
29. Platt, E. J., Bilska, M., Kozak, S. L., Kabat, D., and Montefiori, D. C. (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1 J. Virol. 83, 8289-8292
30. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46, 1896-1905 (Pubitemid 34535213)
31. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., and Hunter, E. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 J. Virol. 74, 8358-8367 (Pubitemid 30666686)
32. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., and Kabat, D. (1998) Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 J. Virol. 72, 2855-2864 (Pubitemid 28175522)
33. Takeuchi, Y., McClure, M. O., and Pizzato, M. (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research J. Virol. 82, 12585-12588
34. Bjorndal, A., Deng, H., Jansson, M., Fiore, J., Colognesi, C., Karlsson, A., Albert, J., Scarlatti, G., Littman, D., and Fenyo, E. (1997) Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype J. Virol. 71, 7478-7487 (Pubitemid 27391688)
35. He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D., and Landau, N. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity J. Virol. 69, 6705-6711
36. Connor, R. I., Chen, B. K., Choe, S., and Landau, N. R. (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes Virology 206, 935-944
37. Page, K. A., Landau, N. R., and Littman, D. R. (1990) Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity J. Virol. 64, 5270-5276 (Pubitemid 20364514)
38. Kutner, R. H., Zhang, X.-Y., and Reiser, J. (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors Nature Protocols 4, 495-505
39. Kimpton, J. and Emerman, M. (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene J. Virol. 66, 2232-2239
40. O'Doherty, U., Swiggard, W. J., and Malim, M. H. (2000) Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding J. Virol. 74, 10074-10080
41. DeLean, A., Munson, P. J., and Rodbard, D. (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves Am. J. Physiol. 235, E97-102
42. Bates, D. M. and Watts, D. G. (1988) Nonlinear Regression Analysis, Wiley, New York.
43. Frey, S., Marsh, M., Gunther, S., Pelchen-Matthews, A., Stephens, P., Ortlepp, S., and Stegmann, T. (1995) Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1 J. Virol. 69, 1462-1472
44. Mkrtchyan, S. R., Markosyan, R. M., Eadon, M. T., Moore, J. P., Melikyan, G. B., and Cohen, F. S. (2005) Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion J. Virol. 79, 11161-11169 (Pubitemid 41170657)
45. Misumi, S., Kudo, A., Azuma, R., Tomonaga, M., Furuishi, K., and Shoji, S. (1997) The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease Biochem. Biophys. Res. Commun. 241, 275-280 (Pubitemid 28020092)
46. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA.